Cassava Sciences

Cassava Sciences is an American clinical stage biotechnology company that develops drugs for neurodegenerative diseases. It was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Cassava Sciences balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Cassava Sciences cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Cassava Sciences multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Cassava Sciences profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Cassava Sciences assets
Cassava Sciences cash flows

Cassava Sciences dividend policy

The company doesn't provide dividends

Cassava Sciences shares

TickerNameTypeNominal valueISINPrice
SAVA:USCassava SciencesCommon share-US14817C1071$30.75
Cassava Sciences news
05.05.2022
Cassava Sciences' GAAP loss for 3 months of 2022 was $17.527 million, up 5 times from $3.526 million in the previous year.
Source: {source} pictogram cassavasciences.com
Pictogram next
01.03.2022
Cassava Sciences' GAAP loss for 2021 was $32.385 million, up 5.1 times from $6.334 million the previous year.
Source: {source} pictogram cassavasciences.com
Pictogram next
17.11.2021
SEC has launched an investigation into Cassava Sciences for manipulating the research results of the company's experimental drug for Alzheimer's disease, sources told the WSJ. The company itself said in a 10-Q report that it had requested documents from government agencies, without specifying which ones.
Source: {source} pictogram wsj.com
Pictogram next
10.11.2021
Cassava Sciences' GAAP loss for 9M 2021 was $18.213 million, up 4.9 times from $3.716 million in the previous year.
Source: {source} pictogram cassavasciences.com
Pictogram next
All Cassava Sciences news
General information
Company nameCassava Sciences
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address7801 North Capital of Texas Highway Suite 260 Austin, TX 78731 United States
Mailing address7801 North Capital of Texas Highway Suite 260 Austin, TX 78731 United States
Websitewww.cassavasciences.com